Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients

Nanobiotix’s Radio-Enhancer NBTXR3 Is Being Tested In Multiple Indications

 
• By Sten Stovall

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.

Radiotherapy
Biotech wants to change how radiation is delivered to tumors • Source: Shutterstock

More from Anticancer

More from Therapy Areas